ResApp Health Limited
(ASX:RAP) has announced further positive results from an adult clinical study into its sound-based respiratory diagnosis technology.
The company has achieved between 91 to 100 percent accuracy in distinguishing adult patients with varying respiratory diseases from those without, using algorithms built using cough like sounds.
The algorithms out performed experienced clinicians during the study, when it came to detecting lower respiratory tract infection in patients initially diagnosed as clear.
ResApp has also reported its paediatric clinic study is progressing well, with three leading U.S. hospitals confirmed as study sites.
ResApp Health Limited reported a net loss of $3.21 million at 30 June 2016.
